G protein-coupled receptors (GPCRs) form the major receptor family encoded by the human genome (\~800 genes), but there is limited diversity of heterotrimeric G proteins through which they couple (16 genes of the α subunit). With each human cell containing multiple GPCRs and multiple G proteins, the molecular determinants that govern the specificity of G protein coupling are unclear. Structural determinants in the coupling of G~S~ to four different GPCRs have been elucidated[@R1]--[@R4], but there is a lack of molecular detail into how the other G protein classes couple. Here we present the electron cryo-microscopy (cryo-EM) structure of the serotonin 5-HT~1B~ receptor (5-HT~1B~R) bound to the agonist donitriptan and coupled to an engineered G~O~ heterotrimer. 5-HT~1B~R is in an active state with the intracellular half of the receptor in a similar conformation observed for the β~2~-adrenoceptor (β~2~AR)^3^ and the adenosine A~2A~ receptor (A~2A~R)^1^ coupled to G~S~. The G~O~-receptor interface is considerably smaller than that observed for the G~S~ interface and the gap between the receptor and the β subunit precludes molecular contacts, unlike that observed for G~S~-coupled receptors. This probably arises due to the subtle differences in interactions between the C-terminus of the G~O~ α subunit compared to G~S~. The molecular variation between the interfaces of G~O~ and G~S~ coupled to GPCRs may contribute significantly to differences in both coupling specificity and the kinetics of signalling.

Heterotrimeric G proteins are divided into four subfamilies[@R5], G~S~, G~i/o~, G~q~ and G~12/13~ and are composed of an α, β and γ subunits. Agonist-bound GPCRs couple to a G protein predominantly through the α subunit, Gα, with relatively few contacts to the β subunit and none to the γ subunit. The overall structure of α subunits in the inactive GDP-bound state is highly conserved[@R6] and they undergo similar conformational changes upon coupling to GPCRs[@R7]. This is characterised by a disorder-to-order transition of the C-terminal half of the α5 helix, that adopts an α-helical conformation upon binding into the cytoplasmic cleft of an activated GPCR[@R8]. The key role of the α5 helix in G protein coupling to GPCRs has long been recognised through mutagenesis studies, which is consistent with it forming 70% of the interactions between Gα and β~2~AR^3^. The amino acid sequence of the α5 helix C-terminus is highly conserved within a G protein subfamily, but it is distinct between different subfamilies. The key role this region plays in determining specificity is indicated by the possibility of changing the coupling specificity of a G protein by mutating the C-terminal region to match that of a different G protein[@R9]. However, other regions of the α subunit can also determine specificity and very often mutations do not transfer simply from one G protein to another[@R10]. Many receptors couple to more than one different G protein, and this coupling may appear different depending upon whether coupling is measured temporally or in an end point assay[@R11]. The structure of β~2~AR coupled to heterotrimeric G~S~ transformed our understanding of how G proteins couple and are activated by GPCRs[@R3], but it does not address the issue of G protein specificity. We have therefore determined the structure of 5-HT~1B~R coupled to heterotrimeric G~O~ to allow a comparison between how G~S~ and G~O~ couple.

There are thirteen GPCRs in the serotonin receptor family[@R12] and they are all found in the central nervous system where they play key roles in all aspects of behaviour[@R13]. A number of structures of 5-HT receptors have been determined in either inactive or active-intermediate states[@R14]--[@R16]. 5-HT~1B~R couples to G~i/o~ and binds the agonist donitriptan with high-affinity[@R17]. G~O~ is the most abundant G protein in the brain and an engineered G~O~, mini-G~O~, was developed to form a heterotrimer with the βγ subunits, which can bind and stabilise the agonist-activated 5-HT~1B~R[@R10]. The individual protein components were expressed, purified and assembled into a complex containing 5-HT~1B~R, donitriptan, mini-G~O~, β~1~ and γ~2~ subunits (see [Methods](#S1){ref-type="sec"}). After gel filtration, the complex was vitrified on electron microscopy grids and the structure determined by single-particle analysis to an overall resolution of 3.8 Å ([Extended Data Fig. 1](#F5){ref-type="fig"}-[4](#F8){ref-type="fig"} and [Extended Data Table 1](#T1){ref-type="table"}), with clear density for the majority of side chains and the agonist donitriptan ([Fig. 1](#F1){ref-type="fig"}; [Extended Data Fig. 2](#F6){ref-type="fig"}). Donitriptan occupies the orthosteric binding site and the serotonin-like moiety of the ligand binds in a region analogous to that found for the native agonists adrenaline[@R18] and adenosine[@R19] ([Fig 1](#F1){ref-type="fig"} and [Extended Data Fig. 5](#F9){ref-type="fig"}). Donitriptan binds in a different mode compared to the ergot family of alkaloids, such as ergotamine and dihydroergotamine[@R15] ([Fig. 1](#F1){ref-type="fig"}). The binding site is formed from amino acid residues in transmembrane helices 3, 5, 6 and 7 (H3, H5, H6 and H7) and extends into the extracellular region to make contacts with H6, H7 and extracellular loop 2 (ECL2). Donitriptan is bound primarily by van der Waals contacts and limited polar interactions with Thr134^3.37^ and Asp129^3.32^, similar to the binding mode of ergotamine. However donitriptan and ergotamine lie on opposite faces of the binding pocket with different rotamers of Phe351^7.35^ and Met337^6.58^ to accommodate the different ligands. The resolution at the ligand binding pocket is slightly lower than for the core of the complex and there are limitations in the interpretation of the experimental data (see [Methods](#S1){ref-type="sec"} and [Extended Data Fig 2](#F6){ref-type="fig"}).

The overall conformation of 5-HT~1B~R in the cryo-EM structure is consistent with the receptor being in a fully active state. Superposition with the active states of β~2~AR^3^ and A~2A~R^1^ shows a high degree of conservation of the cytoplasmic halves of the receptors ([Fig. 2](#F2){ref-type="fig"}). In addition, rotamers of key conserved amino acid residues (Pro^5.50^, Ile^3.40^, Phe^6.44^)[@R8] in the activated receptors are virtually identical, suggesting that 5-HT~1B~R has attained a fully active state. The structure of a 5-HT~1B~R-BRIL fusion was determined previously bound to the agonist ergotamine and was suggested to be in an active intermediate state due to the partial movement of H6 and partial rotamer changes of the key amino acid residues[@R15]. Comparison of the G~O~-coupled 5-HT~1B~R with the ergotamine-bound 5-HT~1B~R shows an 8 Å shift of the cytoplasmic end of H6 (Cα of Lys311), an inward shift of H7/H8 by 2 Å (Cα of Glu374) and rotamer changes of Arg^3.50^, Tyr^5.58^ and Tyr^7.53^ ([Fig. 2](#F2){ref-type="fig"}). Interestingly, the extracellular half of the receptor that forms the orthosteric binding pocket does not change significantly in conformation upon the transition from the active intermediate state to the active G protein-coupled state. This was also observed in conformations of A~2A~R[@R20], but is different from that observed in β~2~AR^3^, which has a different energy landscape[@R21].

The architecture of 5-HT~1B~R coupled to G~O~ is superficially similar to that of the β~2~AR-G~S~ and A~2A~R-G~S~ complexes[@R1],[@R3], but there are critical differences in the details. The interface between 5-HT~1B~R and G~O~ is composed of 9 amino acid residues from 5-HT~1B~R and 13 from the α subunit of G~O~. This compares with 24 residues from β~2~AR and 20 in A~2A~R that make contact to, respectively, 17 and 22 residues in Gα~S~ ([Fig. 3](#F3){ref-type="fig"}). Thus the surface area of G~O~ in contact with the receptor is only 822 Å^2^, compared to 1260 Å^2^ for β~2~AR and 1135 Å^2^ for A~2A~R. All the receptor contacts made by G~O~ are from residues in the α5 helix. In contrast, contacts to β~2~AR and A~2A~R by Gα~S~ also involve regions in S1, S2/S3 and H4/S6 ([Extended Data Fig. 6](#F10){ref-type="fig"}). The overall conformation of Gα~S~ and Gα~O~ coupled to the receptors is very similar ([Extended Data Fig. 7](#F11){ref-type="fig"}). However, inspection of an alignment between the cytoplasmic halves of 5-HT~1B~R, β~2~AR and A~2A~R shows that the α5 helix of Gα~O~ is positioned differently within the receptor compared to Gα~S~ ([Fig. 3](#F3){ref-type="fig"}, [Extended Data Fig. 7](#F11){ref-type="fig"}). There is a 9° or 11° tilt of the N-terminal end of the α5 helix away from the membrane plane (pivot point in the region of I344-N347 in Gα~O~) compared to α5 coupled to β~2~AR and A~2A~R, respectively. The different tilt angles probably arise through the different positions of the C-terminal \~8 amino acid residues of the α5 helices within the receptor. This region contains the major specificity determinants between G proteins[@R7]. The final four amino acid residues in Gα~S~ are Y^H5.23^ELL^H5.26^, compared to C^H5.23^GLY^H5.26^ in Gα~O~ (superscripts refer to the CGN system[@R7]), and they form a 'wavy hook' structure at the end of the α5 helix. In Gα~S~, the π electrons of Tyr^H5.23^ form extensive contacts with the positively charged Arg^3.50^, which forms the boundary between the cytoplasmic cleft where the α5 helix binds and the hydrophobic core of the receptor[@R20]. Similarly, in G~O~ Cys351^H5.23^ interacts with Arg147^3.50^, although only through van der Waals interactions. Thus the α5 helix from both G~O~ and G~S~ penetrate GPCRs to the same degree. In contrast to Gα~S~, in Gα~O~ the single amino acid residue that makes most contacts to the receptor is the C-terminal Tyr354^H5.26^, where the side chain stacks against Arg308^6.29^ in 5-HT~1B~R and also makes a weak polar interaction with the same residue. In Gα~S~ the terminal amino acid Leu394^H5.26^ makes only very few contacts with β~2~AR and is disordered in the A~2A~R-G~S~ structure. In the A~2A~R-mini-G~S~ crystal structure, there are extensive contacts between Glu394^H5.24^ and three Arg residues in the H7/H8 region of the receptor[@R20]; this residue is Gly352^H5.24^ in G~O~ and makes only minor contacts to the receptor. Although it appears from the cryo-EM structure that all the major contacts between 5-HT~1B~R and Gα~O~ are mediated by the α5 helix of Gα~O~, there is weak density for H5 and H6 of 5-HT~1B~R that extends towards the α4 helix in Gα~O~ ([Extended Data Figure 1](#F5){ref-type="fig"}). It is known that mutations in α4 can affect coupling to 5-HT~1B~R[@R22], but it is unclear from the structure whether this is because direct contacts to the receptor were removed or whether there was a secondary effect of the mutation on the structure of Gα~O~.

The coupling specificity determinants for G proteins are found predominantly at the C-terminus of Gα in the α5 helix and the wavy hook. The architecture of this region is virtually identical in Gα~S~ and Gα~O~, but the differences in amino acid sequence ([Extended Data Figs 6](#F10){ref-type="fig"} & [8](#F12){ref-type="fig"}) results in Gα~S~ being bulkier than Gα~O~ in the terminal five residues ([Extended Data Fig 9](#F13){ref-type="fig"}). This may be sufficient in some G~O~-specific GPCRs to prevent coupling of G~S~ as the narrower crevice in the GPCR may exclude the wider end of G~S~. Conversely, the wider crevice in G~S~ coupled receptors may allow coupling of G~O~, provided there are suitable residues lining the crevice to form a good interface. This last caveat raises the problem of predicting G protein coupling specificity. Although the structure and mechanism of GPCRs are highly conserved[@R8],[@R23], GPCRs have diversified significantly in humans so there is considerable sequence heterogeneity with apparently little or no specific amino acid conservation correlating with the subtype of G protein a receptor couples to[@R24]. In addition, there is the potential for different conformations of GPCRs[@R25], which suggests that the mode of G protein coupling could be different between different receptors. This is observed with a transducin peptide coupled to opsin[@R26], where there is a \~30° difference in angle between the α5 helix compared to the α5 helix of G~O~, even though the G proteins are in the same family. More structures will be required to evaluate the diversity of G protein coupling.

The specific differences in packing at the C-terminus of G~O~ compared to G~S~ have a disproportionate effect on the whole G protein due to their amplification through the different insertion angle of the α5 helix. This results in a change in the tilt of the whole G protein, which moves away from the membrane plane and results in a gap between the rest of the G protein and 5-HT~1B~R. Therefore there are no contacts between 5-HT~1B~R and Gβ subunits, and the only contacts made to Gα are with the α5 helix. This is in marked contrast to the relatively close packing of G~S~ to both A~2A~R and β~2~AR ([Fig 4](#F4){ref-type="fig"}). Given the conserved mechanism of GPCR[@R23] and G protein activation[@R7], it is likely that when considering other GPCRs activated by diffusible ligands the small interface between 5-HT~1B~R and G~O~ is a common feature of the G~i/o~ family compared to G~S~. A likely consequence of the small receptor-G~i/o~ interface is that G~i/o~ may have a faster rate of dissociation than G~S~ when compared with the same GPCR. The kinetics of all the steps in GPCR signalling pathways are thought to have a profound effect on dictating which particular signalling event results from agonist binding to a defined receptor in a specific cell type[@R27],[@R28]. A combination of structural data and kinetic analyses will be essential to unravel the complexities of this system.

Methods {#S1}
=======

Expression and purification of 5-HT~1B~R {#S2}
----------------------------------------

N-terminally truncated wild type human 5-HT~1B~R (residues 34-390) was modified to contain a C-terminal histidine tag (His~10~) and TEV protease cleavage site[@R10]. The L138W^3.41^ mutation was introduced to increase thermostability. Recombinant baculoviruses expressing 5-HT~1B~R were prepared using the flashBAC ULTRA system (Oxford Expression Technologies). *Trichoplusia ni* cells (Expression Systems; not authenticated by the authors and not tested for mycoplasma by the authors) were grown in suspension in ESF921 media (Expression Systems) to a density of 3x10^6^ cells/ml, infected with 5-HT~1B~R baculovirus and incubated for 48 h. Cells were harvested and membranes prepared by two ultracentrifugation steps in 20 mM HEPES pH7.5, 1 mM EDTA, 1 mM PMSF. Membranes were resuspended finally in 20 mM HEPES pH7.5, 500 mM NaCl, 5 mM MgCl~2~, 10 mM Imidazole, and Complete™ protease inhibitors (Roche) and flash frozen in liquid nitrogen and stored at -80°C.

Membranes from 2 L of cells were solubilised with 2% n-decyl-β-D-maltopyranoside (DM) on ice for 30 min in the presence of 1 μM donitriptan hydrochloride. The sample was clarified by ultracentrifugation and loaded onto a 5 ml Ni-NTA column (Generon). The column was equilibrated and sample loaded using buffer A (20 mM HEPES pH 7.5, 500 mM NaCl, 1 mM MgCl~2~, 50 mM imidazole, 1 μM donitriptan hydrochloride, 0.15% DM), and eluted with buffer B (20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM MgCl~2~, 300 mM imidazole, 1 μM donitriptan hydrochloride, 0.15% DM). The eluate was concentrated using a 50 kDa cut-off Amicon centrifugal ultrafiltration unit (Millipore), and exchanged into desalting buffer (20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM MgCl~2~, 1 μM donitriptan hydrochloride, 0.15% DM) using a PD10 column (GE Healthcare). 2.5 mg of TEV protease were added, and the sample was incubated on ice overnight. TEV protease was removed by negative purification on Ni^2+^-NTA resin. The sample was concentrated to \~1 ml and loaded onto a Superdex 200 column (GE Healthcare). Peak fractions corresponding to monomers of receptors were pooled and concentrated. A typical yield was 1-2 mg of pure 5-HT~1B~R per litre of culture.

Formation of a 5-HT~1B~R-heterotrimeric mini-G~O~ complex {#S3}
---------------------------------------------------------

Purified 5-HT~1B~R was mixed with a 1.2-fold molar excess of mini-G~O1~β~1~γ~2~ in the presence of apyrase (0.2 U/mL) and the mixture was incubated on ice overnight[@R10]. The sample was loaded on to a Superdex 200 column. Peak fractions, containing the 5-HT~1B~R--mini-G~O1~β~1~γ~2~ complex, were pooled and concentrated to 4 mg/ml.

Cryo-grid preparation and data collection {#S4}
-----------------------------------------

Cryo-EM grids were prepared by applying 3 µl of sample (at a protein concentration of 2.2 mg/ml) on glow discharged holey gold grids (Quantifoil Au 1.2/1.3 300 mesh). Excess sample was removed by blotting with filter paper for 3-4 seconds prior to plunge-freezing in liquid ethane using a FEI Vitrobot Mark IV at 100% humidity and 4°C. Images were collected on a FEI Titan Krios microscope at 300kV using a Falcon III detector in electron counting mode and a Volta phase plate. EPU software (FEI) was used for automatic data collection. Data were collected in nine independent sessions to give a total of 5,737 movies. Each micrograph was collected as 75 movie frames at a dose rate of 0.5 e^-^/pixel/sec (0.4 e^-^/Å^2^ per frame) for 60 seconds, with a total accumulated dose of \~30 e^-^/Å^2^. The magnification used was 75,000x yielding a pixel size of 1.06 Å/pixel.

Data processing and model building {#S5}
----------------------------------

RELION-2.1 was used for all data processing[@R31] unless otherwise specified. Since data were pooled from nine independent sessions we provide here the general strategy for data collection and processing, while precise particle numbers for a representative data set are presented in [Extended Data Fig 3](#F7){ref-type="fig"}. Overall, drift, beam induced motion and dose weighting were corrected with MotionCor2[@R32] using 5 x 5 patches. CTF fitting and phase shift estimation were performed using Gctf-v0.1.06[@R33] which yielded the characteristic pattern of phase shift accumulation over time for each position. Generally, 40 images were taken at each Volta phase plate position. Auto-picking was performed with a Gaussian blob as a template[@R34] which readily resulted in optimal particle picking. Particles were extracted in a box of 150 pixels (159 Å) and inputted into a one or two reference-free 2D classification (if the majority of 2D classes had non-recognizable or low-quality features, then the selected particles belonging to quality classes were taken to a second round of 2D classification). An *ab initio* model was generated using 10,000 particles with RELION 2.1[@R35] in the first data collection and used throughout. The resulting particles after 2D classification where then used for 3D classification in both three and four classes simultaneously in order to check for consistency in 3D classification and to generate models with different numbers of particles. The models with best defined features were selected for refinement either on their own or together with a second class from the same 3D classification (if more than one quality model were present). The particles that reached the highest resolution after gold-standard resolution estimation were saved. Particles obtained in a similar fashion from the different sessions were then merged and refined together. During refinement, the low-pass filter effect of the Wiener filter in the regularised likelihood optimisation algorithm was relaxed through the use of a regularisation parameter (T=3). This allowed the refinement algorithm to consider higher spatial frequencies in the alignment of the individual particles. Nevertheless, both half-reconstructions were kept completely separately, and the final resolution estimate (at the post-processing stage in RELION) was based on the standard FSC between the two unfiltered half-reconstructions. The final model contained 730,118 particles and reached an overall resolution of 3.78 Å with side chains visible for most of the complex ([Extended Data Figs 1](#F5){ref-type="fig"} and [2](#F6){ref-type="fig"}). Local resolution estimates were calculated with Resmap[@R36] showing a core of the protein at \~3.5 Å resolution and an extracellular region of the receptor and βγ N-termini at poorer resolution with the worst regions reaching \~5 Å ([Extended Data Fig 1](#F5){ref-type="fig"}). Signal subtraction of the DM micelle did not improve the quality of the map upon refinement.

Model building and refinement was carried out using the CCP-EM software suite[@R37]. The 5-HT~1B~R-ergotamine crystal structure was used as a starting model (PDB ID 4IAR)[@R15] for receptor building. 5-HT~1B~R was modelled from residue L45 to R385. Although density was present from Y38 and this region seems to adopt a similar conformation to the 5-HT~1B~R crystal structure, the poor resolution in this region prompted us to leave it unmodelled. Residues R188 to V196 in the ECL2 and I339 to C344 in ICL3 were flexible with absent or very poor map density and were therefore, not modelled. For the same reason residues K241 to L304 forming the large 5-HT~1B~R ICL3 loop were left unmodelled. Mini-G~O~ was modelled from residue L5 to Y354 following native Gα~O~ numbering. Modifications in Gα~O~ to obtain mini-G~O~ are explained in Nehme et al. ([Extended Data Figure 7](#F11){ref-type="fig"})[@R10]. Although β and γ subunits were modelled using the available crystal structures, poor density was found for both N-termini, with the whole of the γ subunit having poor density. For this reason the worst regions of these subunits were modelled as poly-alanine. Initial manual model building was performed in Coot[@R38] following a jelly-body refinement in REFMAC5[@R39]. Donitriptan coordinates and library were created with JLigand[@R40] and manually fitted into the density using sphere real space refinement in Coot. Restraints were generated with ProSMART[@R41] in order to maintain structural features in regions of poorer density. B factors were reset to 40 Å^2^ prior to refinement. The model then followed cycles of manual modifications in Coot and restraint refinement in REFMAC5. The final model achieved good geometry ([Extended Data Table 1](#T1){ref-type="table"}) with validation of model performed in Coot, Molprobity[@R42] and EMRinger[@R43]. The goodness of fit of the model to the map was carried out using Phenix[@R44] using a global model-*vs*-map FSC correlation ([Extended Data Fig 2](#F6){ref-type="fig"}). Overfitting in refinement was monitored throughout using FSC~work~/FSC~test~[@R45].

Note on limitations on the interpretation of density in the ligand binding pocket {#S6}
---------------------------------------------------------------------------------

The ligand binding pocket of 5-HT~1B~R is occupied by a single molecule of the agonist donitriptan. Despite the resolution varying between 3.8 Å to 4.3 Å in this region, estimated from the local resolution map ([Extended Data Fig 1](#F5){ref-type="fig"}), the density allowed modelling of the position and orientation of donitriptan and the majority of the amino acid side chains in the pocket. However, the resolution limits the accuracy of the refined coordinates and care must be taken when analysing the precise details of any potential interactions. The best resolution is towards the centre of the membrane bilayer and gets worse towards the extracellular surface of the receptor. The ligand has been modelled using real space refinement taking into account the location of nearby residues as well as using a library of restraints with allowed conformations of donitriptan. The density allowed modelling of the position and orientation of the donitriptan molecule, with the indole group buried deep in the orthosteric binding pocket and the remainder of the ligand protruding towards the extracellular surface.

Clear interpretable density is found for large aromatic groups, while density is poorer for residues with smaller side chains such as Ser334^6.55^ and Ser212^5.42^. Tyr359^7.43^, Phe330^6.51^ and Phe331^6.52^ are positioned around the indole group at the base of the pocket and Phe351^7.35^ interacts with the donitriptan aromatic moiety at the most extracellular region. Met337^6.58^ is located in a region of poor density and has been modelled so that is oriented away from the pocket and interacting with the aromatic group of donitriptan. This was concluded based on interpretation of maps with different sharpening levels, but its rotamer cannot be assigned with confidence. The orientation of the primary amine on the serotonin moiety in donitriptan and the adjacent side chain of Asp129^3.32^ cannot be confidently assigned due to poor density. However, Asp129^3.32^ is absolutely conserved in all the human serotonin GPCRs and forms a hydrogen bond with ergotamine in the high-resolution crystal structure of 5-HT~1B~R. We have therefore modelled Asp129^3.32^ in a similar rotamer to make a potential hydrogen bond with this primary amine in donitriptan, despite the lack of density for both the primary amine and the carboxyl group of Asp129^3.32^.

Extended Data {#S7}
=============

![Cryo-EM single particle reconstruction of the 5-HT~1B~R--G~O~ complex structure.\
**a**, Representative micrograph (magnification 75,000x, defocus -0.6 μm) of the 5-HT~1B~R--G~O~ complex collected using a Titan Krios with the Falcon III detector and Volta phase plate. **b**, Representative 2D class averages of the 5-HT~1B~R--G~O~ complex. **c**, FSC curve of the final reconstruction showing an overall resolution of 3.8 Å using the gold-standard FSC of 0.143. Both masked and unmasked FSC curves are shown to highlight the lack of masking artefacts. **d**, Final reconstruction coloured by subunit showing a zoom on the weak density for ICL3. The zoomed region corresponds to a map sharpened with B = -50 to remove noise from lower density levels. **e**, Local resolution estimation of the 5-HT~1B~R map as calculated by Resmap.](emss-77891-f005){#F5}

![Cryo-EM map quality and model validation.\
**a**, transmembrane helices of 5-HT~1B~R; **b**, the α5 helix of G~O~; **c**, donitriptan and the neighbouring side chains in the orthosteric binding site; **d**, Fourier shell correlation of the refined model *versus* the map (green curve) and FSC~work~/FSC~test~ validation curves (blue and red curves, respectively).](emss-77891-f006){#F6}

![Flow-chart of data processing.\
Micrographs were collected during nine sessions on the Titan Krios (either 24 h or 48 h) and each session was processed independently. The number of images and particles for one 48 h session is indicated on the flowchart as a guide. At the bottom of the figure, the final number of particles is shown. Each dataset was corrected separately for drift, beam induced motion and radiation damage. After CTF estimation, particles were picked using a Gaussian blob and submitted to either one or two rounds of reference-free 2D classification (see [Methods](#S1){ref-type="sec"}). A 3D classification was performed on the selected particles using an *ab initio* model generated from ten thousand particles. Classification was performed in parallel in three and four classes. The models with best features were refined on their own; if there were two classes of similar high quality, these were then re-refined together (the resolution of the models refers to that after refinement and calculation of gold-standard FSC=0.143). The set of particles that obtained the best map quality and resolution were saved and merged with the best particles from other datasets. A final model with 730,118 particles was refined and achieved a global resolution of 3.78 Å.](emss-77891-f007){#F7}

![Modelling quality of the 5-HT~1B~R structure.\
**a**, Amino acid sequence of 5-HT~1B~R construct used in the cryo-EM structure determination. Residues are colored according to how they have been modelled: black, good density allows the side chain to be modelled; red, limited density for the side chain present and therefore the side chain has been truncated to Cβ; blue, no density observed and therefore the residue was not modelled. Regions highlighted in grey represent the transmembrane α-helices and amphipathic helix 8 is highlighted in yellow. **b**, Model of 5-HT~1B~R showing the Cα positions of amino acid residues with poor density (spheres) and regions unmodelled (dotted lines).](emss-77891-f008){#F8}

![Superposition of donitriptan, adrenaline and adenosine.\
5-HT~1B~R, β~2~AR^3^ and A~2A~R^1^ were superimposed (Pymol) over the whole of the receptor and the ligands coloured accordingly: green, donitriptan; pink, adrenaline; blue, adenosine.](emss-77891-f009){#F9}

![Comparison of the amino acid sequences of the α subunits of G~O~ and G~S~.\
Diamonds above the sequences identify the amino acid residues in Gα~s~ where the side chains that make atomic contacts to residues in either β~2~AR (β2 con) or A~2A~R (2A con). Ovals above the sequences identify the amino acid residues in Gα~s~ where only the main chain atoms make contacts to the receptor. Secondary structural elements are indicated as grey bars and the CGN system of numbering is shown.](emss-77891-f010){#F10}

![Similarity of Gα structures and the difference poses of the α5 helices in Gα~O~ and Gα~S~ coupled to receptors.\
**a,** The structures of the α subunits coupled to 5-HT~1B~R, β~2~AR^3^ and A~2A~R^1^ were superimposed over the whole of their sequence in Pymol; blue, Gα~O~ coupled to 5-HT~1B~R; green, Gα~S~ coupled to A~2A~R; Gα~S~ coupled to β~2~AR. **b**, 5-HT~1B~R (blue), β~2~AR^3^ (green) and A~2A~R^1^ (red) were superimposed based on H3, H5 and H6. Two different views are shown with the red arrows indicating differences in orientation of Gα~S~ and Gα~O~.](emss-77891-f011){#F11}

![Alignment of the amino acid sequences of G~O~ and G~i~ α subunits.\
Sequences in grey correspond to the α-helical region that do not make contact to GPCRs and was deleted during the construction of mini-G~O~. Secondary structural elements are depicted as grey bars with the CGN system shown to aid comparisons. Amino acids are highlighted as follows: pink, stabilizing residues required to generate mini-G~O~; yellow; residues in Gα~O~ that are different from residues conserved in all three Gα~i~ sequences; blue, residues that are non-conserved in Gα~i~ sequences. \# represents the affinity tag on mini-Go used for purification (MGHHHHHHENLYFQG).](emss-77891-f012){#F12}

![Comparison between the α5 helices of G~S~ and G~O~.\
The α5 helices in the cryo-EM structures of A~2A~R-G~S~ (carbon, green) and 5-HT~1B~R-G~O~ (carbon, light blue) were aligned (Pymol) along their whole sequence and displayed in different poses: **a**, cartoon depiction; **b**, G~S~ (green spheres), G~O~, (blue sticks); **c**, G~O~ (blue spheres), G~S~, (green sticks).](emss-77891-f013){#F13}

###### Data collection and refinement statistics.

  ---------------------------------------------------------------------------------------
                                                                 5-HT~1B~ - MiniG~O~βγ\
                                                                 (EMDB-4358)\
                                                                 (PDB 6G79)
  -------------------------------------------------------------- ------------------------
  **Data collection and processing**                             

  Magnification                                                  75,000x

  Voltage (kV)                                                   300

  Electron exposure (e-/Å^2^)                                    30

  Defocus range (µm)                                             -0.3 to -1.0

  Pixel size (Å)                                                 1.06

  Symmetry imposed                                               CI

  Initial particle images[1](#TFN1){ref-type="table-fn"} (no.)   1,249,822

  Final particle images (no.)                                    730,118

  Map resolution (Å)                                             3.78

      FSC threshold                                              0.143

  Map resolution range[2](#TFN2){ref-type="table-fn"} (Å)        \~3.4 to \~4.6

  **Refinement**                                                 

  Initial model used (PDB code)                                  5G53, 3SN6

  Model resolution[3](#TFN3){ref-type="table-fn"} (Å)            3.9

      FSC threshold                                              0.5

  Map sharpening *B* factor (Å^2^)                               -200

  Model composition                                              

      Non-hydrogen atoms                                         6053

      Protein residues                                           6023

      Ligands                                                    30

  *B* factors (Å^2^)                                             

      Protein                                                    97

      Ligand                                                     108

  R.m.s. deviations                                              

      Bond lengths (Å)                                           0.007

      Bond angles (°)                                            1.02

  Validation                                                     

      MolProbity score                                           1.07

      Clashscore                                                 0.61

      Poor rotamers (%)                                          0.56

      EMRinger score                                             2.34

  Ramachandran plot                                              

      Favored (%)                                                94.64

      Allowed (%)                                                4.88

      Disallowed (%)                                             0.48
  ---------------------------------------------------------------------------------------

After 2D classification

Local resolution range

Resolution at which FSC between map and model is 0.5
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![Overall cryo-EM reconstruction of the 5-HT~1B~R--G~O~ heterotrimer complex.\
The density for the cryo-EM map (sharpened with a B factor of -200) is coloured according to the subunit. The inset shows the orthosteric binding pocket in 5-HT~1B~R (light blue) with donitriptan depicted as sticks (green, carbon) and its density in the cryo-EM map. The lower panel shows a superposition of ergotamine-bound 5-HT~1B~R (pale grey, PDB ID 4IAR)[@R15] and donitriptan-bound 5-HT~1B~R (pale blue). Donitriptan (green, carbon) and ergotamine (orange, carbon) are depicted as sticks.](emss-77891-f001){#F1}

![G~O~-coupled 5-HT~1B~R is in an active conformation.\
**a-c,** Superposition of G protein-bound receptors: 5-HT~1B~R (blue), A~2A~R (red)^1^ and β~2~AR (green)^3^ based on H3, H5 and H6. Key amino acid residues involved in receptor activation are displayed as sticks. **d-f,** Superposition of G~O~-coupled 5-HT~1B~R (blue) and the active-intermediate state of 5-HT~1B~R bound to ergotamine (pale grey), based on alignment of the whole receptor. Conformational changes involved in receptor activation are highlighted (red arrows) and key residues are shown as sticks with the density from the cryo-EM map (mesh). **a** and **d**, view parallel to the membrane plane; **b** and **e**, enlarged view of the conserved core of the receptors; **c** and **f**, view from the cytoplasmic face of the membrane.](emss-77891-f002){#F2}

![G~O~ coupling to the 5-HT~1B~R.\
**a**, C-terminal end of Gα~O~ (yellow sticks) inserted into the cytoplasmic cleft of 5-HT~1B~R (blue cartoon). Cryo-EM density is depicted as a mesh. **b**, Superposition of 5-HT~1B~R (blue), A~2A~R (red)^1^ and β~2~AR (green)^3^ based on alignment of H3, H5 and H6. The different poses of the C-termini of G~S~ and G~O~ coupled to the respective receptors are shown. **c**, Amino acid residues in 5-HT~1B~R, A~2A~R and β~2~AR that make contact to the respective Gα subunits they are coupled to are shown in colours that reflect biophysical properties of the residues; green, hydrophobic; yellow, hydrophilic, red, acidic; blue, basic. Residues coloured in white do not make contact to the relevant Gα. The amino acid alignment was created in GPCRdb[@R29] and secondary structural elements and the Ballesteros-Weinstein numbers[@R30] are depicted. **d**, Snake plot of 5-HT~1B~R created in GPCRdb with residues making contact to Gα~O~ coloured according to their biophysical properties. Regions in grey were disordered in the cryo-EM map. **e**, Cartoon of secondary structural elements in Gα~O~ and amino acid residues that make contact to 5-HT~1B~R are depicted and coloured according to their biophysical properties.](emss-77891-f003){#F3}

![Comparison of G~S~ coupling *vs* G~O~ coupling.\
**a,** Cartoon of β~2~AR (green) coupled to G~S~ (PDB ID 3SN6)[@R3]. The α-helical domain of the Gα has been removed for clarity. **b-d**, surface rendered views of the interface between a receptor and G protein: **b**, β~2~AR (green) and G~S~; **c**, A~2A~R^1^ (red) and G~S~; **d**, 5-HT~1B~R (blue) and G~O~.](emss-77891-f004){#F4}
